

**Hikma Pharmaceuticals PLC - EIP Vesting**

LONDON, 7 March 2024: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) ("**Hikma**") (LEI: 549300BNS685UXH4JI75) announces that the following Persons Discharging Managerial Responsibility ("**PDMR**") have received shares as a result of the vesting of their conditional share awards which were granted on 25 February 2022 under the 2014 Executive Incentive Plan ("**EIP**") Element B and 25 February 2021 under the EIP Element C.

**Notification and public disclosure of transactions by persons discharging managerial responsibilities**

**Bassam Kanaan**

<b>1</b>	<b>Details of the person discharging managerial responsibilities / person closely associated</b>		
a)	Name	Bassam Kanaan	
<b>2</b>	<b>Reason for the notification</b>		
a)	Position/status	PDMR	
b)	Initial notification /Amendment	Initial notification	
<b>3</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>		
a)	Name	Hikma Pharmaceuticals PLC	
b)	LEI	549300BNS685UXH4JI75	
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>		
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083	
b)	Nature of the transaction	Shares acquired from the vesting of conditional awards under the EIP Element B and EIP Element C. All Shares were retained.	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		Nil	EIP Award, Element B: 20,588
		Nil	EIP Award, Element C: 13,378
d)	Aggregated information	Price(s): nil Volume(s): 33,966	
e)	Date of the transaction	6 March 2024	
f)	Place of the transaction	London Stock Exchange (XLON)	

**Julie Hill**

<b>1</b>	<b>Details of the person discharging managerial responsibilities / person closely associated</b>		
a)	Name	Julie Hill	
<b>2</b>	<b>Reason for the notification</b>		

a)	Position/status	PDMR	
b)	Initial notification /Amendment	Initial notification	
<b>3</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>		
a)	Name	Hikma Pharmaceuticals PLC	
b)	LEI	549300BNS685UXH4JI75	
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>		
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083	
b)	Nature of the transaction	Shares acquired from the vesting of conditional awards under the EIP Element B.	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		Nil	5,339
d)	Aggregated information	Price(s): nil Volume(s): 5,339	
e)	Date of the transaction	6 March 2024	
f)	Place of the transaction	London Stock Exchange (XLON)	
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>		
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083	
b)	Nature of the transaction	Shares sold to cover tax following the vesting of conditional awards under the EIP Element B.	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£19.275	2,190
d)	Aggregated information	Price(s): £19.275 Volume(s): 2,190 Total(s): £42,211.36	
e)	Date of the transaction	6 March 2024	
f)	Place of the transaction	London Stock Exchange (XLON)	

Helen Middlemist  
Group Company Secretary  
+44 (0)20 7399 2760

7 March 2024

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHBXGDXBUGDGR